bluebird bio (NASDAQ:BLUE), Analyst Ratings, Price Targets, Predictions

The latest price target for bluebird bio (NASDAQ: BLUE) was reported by Barclays on August 5, 2022. The analyst firm set a price target for $5.00 expecting BLUE to fall to within 12 months (a possible -25.60% downside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by Barclays, and bluebird bio upgraded their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.

While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a upgraded with a price target of $3.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $6.72, which is out of the analyst’s predicted range.